

Erratum

Erratum to “Angiotensin II, Aldosterone, and Anti-Inflammatory Lymphocytes: Interplay and Therapeutic Opportunities”

Daniel Arthur B. Kasal¹ and Ernesto L. Schiffrin²

¹*Departamento de Clínica Médica, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Avenida. 28 de Setembro 77, 3º andar, Sala 329, Vila Isabel, 20551-030 Rio de Janeiro, RJ, Brazil*

²*Department of Medicine and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, QC, Canada H3T 1E2*

Correspondence should be addressed to Daniel Arthur B. Kasal, kasald@netscape.net

Received 25 June 2012; Accepted 9 July 2012

Copyright © 2012 D. A. B. Kasal and E. L. Schiffrin. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The following corrections should be considered.

- (i) In the text on page 3, replace the number of reference [26] by [25].
- (ii) In the text on page 3, replace the number of reference [27] by [26].
- (iii) In the text on page 3, replace the number of reference [28] by [27].
- (iv) In the text on page 3, replace the number of reference [29] by [28].
- (v) In the text on page 3, replace the number of reference [30] by [29].
- (vi) In the text on page 3, replace the number of reference [31] by [30].
- (vii) In the text on page 3, replace the number of reference [32] by [31].
- (viii) In the text on page 3, replace the number of reference [33] by [32].
- (ix) In the text on page 3, replace the number of reference [34] by [33].
- (x) In the text on page 3, replace the number of reference [35] by [34].
- (xi) In the text on page 3, replace the number of reference [36] by [35].
- (xii) In the text on page 3, replace the number of reference [37] by [36].

(xiii) In the text on page 4, replace the number of reference [25] by [37].

(xiv) In the legend of Figure 1, replace the number of reference [25] by [37].

(xv) Please consider the following corrected reference list for paper.

References

- [1] C. M. Lawes, S. V. Hoorn, and A. Rodgers, “Global burden of blood-pressure-related disease, 2001,” *The Lancet*, vol. 371, no. 9623, pp. 1513–1518, 2008.
- [2] L. M. Brown, “Essential hypertension,” *National Medical Association*, vol. 21, no. 1, pp. 1–4, 1929.
- [3] G. Londres, Ed., *Hipertensão Arterial*, vol. 235, Livraria Agir Editora, Rio de Janeiro, Brazil, 1945.
- [4] R. Tigerstedt and P. G. Bergman, “Niere und Kreislauf,” *Skandinavisches Archiv für Physiologie*, vol. 8, pp. 223–271, 1898.
- [5] F. N. White and A. Grollman, “Autoimmune factors associated with infarction of the kidney,” *Nephron*, vol. 204, pp. 93–102, 1964.
- [6] B. Rodríguez-Iturbe, H. Pons, Y. Quiroz et al., “Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure,” *Kidney International*, vol. 59, no. 6, pp. 2222–2232, 2001.
- [7] A. Virdis and E. L. Schiffrin, “Vascular inflammation: a role in vascular disease in hypertension?” *Current Opinion in Nephrology and Hypertension*, vol. 12, no. 2, pp. 181–187, 2003.

- [8] C. de Ciuceis, F. Amiri, P. Brassard, D. H. Endemann, R. M. Touyz, and E. L. Schiffrin, "Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 25, no. 10, pp. 2106–2113, 2005.
- [9] P. Wenzel, M. Knorr, S. Kossmann et al., "Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction," *Circulation*, vol. 124, no. 12, pp. 1370–1381, 2011.
- [10] J. Shao, M. Nangaku, T. Miyata et al., "Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury," *Hypertension*, vol. 42, no. 1, pp. 31–38, 2003.
- [11] T. J. Guzik, N. E. Hoch, K. A. Brown et al., "Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction," *Journal of Experimental Medicine*, vol. 204, no. 10, pp. 2449–2460, 2007.
- [12] C. Nataraj, M. I. Oliverio, R. B. Mannon et al., "Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway," *Journal of Clinical Investigation*, vol. 104, no. 12, pp. 1693–1701, 1999.
- [13] M. Jurewicz, D. H. McDermott, J. M. Sechler et al., "Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation," *Journal of the American Society of Nephrology*, vol. 18, no. 4, pp. 1093–1102, 2007.
- [14] N. E. Hoch, T. J. Guzik, W. Chen et al., "Regulation of T-cell function by endogenously produced angiotensin II," *American Journal of Physiology*, vol. 296, no. 2, pp. R208–R216, 2009.
- [15] P. J. Marvar, S. R. Thabet, T. J. Guzik et al., "Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension," *Circulation Research*, vol. 107, no. 2, pp. 263–270, 2010.
- [16] A. Fiebeler, F. Schmidt, D. N. Müller et al., "Mineralocorticoid receptor affects AP-1 and nuclear factor- κ B activation in angiotensin II-induced cardiac injury," *Hypertension*, vol. 37, no. 2, pp. 787–793, 2001.
- [17] R. Rocha, A. E. Rudolph, G. E. Friedrich et al., "Aldosterone induces a vascular inflammatory phenotype in the rat heart," *American Journal of Physiology*, vol. 283, no. 5, pp. H1802–H1810, 2002.
- [18] M. F. Neves, F. Amiri, A. Viridis, Q. N. Diep, and E. L. Schiffrin, "Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy," *Canadian Journal of Physiology and Pharmacology*, vol. 83, no. 11, pp. 999–1006, 2005.
- [19] A. Viridis, M. F. Neves, F. Amiri, E. Viel, R. M. Touyz, and E. L. Schiffrin, "Spironolactone improves angiotensin-induced vascular changes and oxidative stress," *Hypertension*, vol. 40, no. 4, pp. 504–510, 2002.
- [20] I. Z. Jaffe and M. E. Mendelsohn, "Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells," *Circulation Research*, vol. 96, no. 6, pp. 643–650, 2005.
- [21] A. J. Rickard and M. J. Young, "Corticosteroid receptors, macrophages and cardiovascular disease," *Journal of Molecular Endocrinology*, vol. 42, no. 6, pp. 449–459, 2009.
- [22] E. Leibovitz, T. Ebrahimiyan, P. Paradis, and E. L. Schiffrin, "Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction," *Journal of Hypertension*, vol. 27, no. 11, pp. 2192–2200, 2009.
- [23] X. L. Wang, D. L. Rainwater, J. F. VandeBerg, B. D. Mitchell, and M. C. Mahaney, "Genetic contributions to plasma total antioxidant activity," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 21, no. 7, pp. 1190–1195, 2001.
- [24] Y. Taniyama and K. K. Griendling, "Reactive oxygen species in the vasculature: molecular and cellular mechanisms," *Hypertension*, vol. 42, no. 6, pp. 1075–1081, 2003.
- [25] M. Sedeek, R. L. Hébert, C. R. Kennedy, K. D. Burns, and R. M. Touyz, "Molecular mechanisms of hypertension: role of Nox family NADPH oxidases," *Current Opinion in Nephrology and Hypertension*, vol. 18, no. 2, pp. 122–127, 2009.
- [26] E. Y. Lee, M. S. Shim, M. J. Kim, S. Y. Hong, Y. G. Shin, and C. H. Chung, "Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes," *Experimental and Molecular Medicine*, vol. 36, no. 1, pp. 65–70, 2004.
- [27] N. J. Brown, "Aldosterone and vascular inflammation," *Hypertension*, vol. 51, no. 2, pp. 161–167, 2008.
- [28] D. J. Kelly, A. J. Cox, R. M. Gow, Y. Zhang, B. E. Kemp, and R. E. Gilbert, "Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo," *Hypertension*, vol. 44, no. 2, pp. 195–202, 2004.
- [29] C. A. Akdis and M. Akdis, "Mechanisms and treatment of allergic disease in the big picture of regulatory T cells," *Journal of Allergy and Clinical Immunology*, vol. 123, no. 4, pp. 735–746, 2009.
- [30] B. M. Hall, M. E. Jelbart, K. E. Gurley, and S. E. Dorsch, "Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/inducer cells," *Journal of Experimental Medicine*, vol. 162, no. 5, pp. 1683–1694, 1985.
- [31] B. R. Powell, N. R. M. Buist, and P. Stenzel, "An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy," *Journal of Pediatrics*, vol. 100, no. 5, pp. 731–737, 1982.
- [32] X. Valencia and P. E. Lipsky, "CD4⁺CD25⁺FoxP3⁺ regulatory T cells in autoimmune diseases," *Nature Clinical Practice Rheumatology*, vol. 3, no. 11, pp. 619–626, 2007.
- [33] M. C. Rodriguez-Galan, J. H. Bream, A. Farr, and H. A. Young, "Synergistic effect of IL-2, IL-12, and IL-18 on thymocyte apoptosis and Th1/Th2 cytokine expression," *Journal of Immunology*, vol. 174, no. 5, pp. 2796–2804, 2005.
- [34] P. Pandiyan, L. Zheng, S. Ishihara, J. Reed, and M. J. Lenardo, "CD4⁺CD25⁺Foxp3⁺ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4⁺ T cells," *Nature Immunology*, vol. 8, no. 12, pp. 1353–1362, 2007.
- [35] Y. Belkaid, "Regulatory T cells and infection: a dangerous necessity," *Nature Reviews Immunology*, vol. 7, no. 11, pp. 875–888, 2007.
- [36] M. I. Garin, N. C. Chu, D. Golshayan, E. Cernuda-Morollón, R. Wait, and R. I. Lechler, "Galectin-1: a key effector of regulation mediated by CD4⁺CD25⁺ T cells," *Blood*, vol. 109, no. 5, pp. 2058–2065, 2007.
- [37] T. Barhoumi, D. A. Kasal, M. W. Li et al., "T Regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury," *Hypertension*, vol. 57, no. 3, pp. 469–476, 2011.
- [38] D. A. Kasal, T. Barhoumi, M. W. Li et al., "T regulatory lymphocytes prevent aldosterone-induced vascular injury," *Hypertension*, vol. 59, no. 2, pp. 324–330, 2012.

- [39] N. M. Al-Daghri, O. S. Al-Attas, M. S. Alokail et al., "Gender-specific associations between insulin resistance, hypertension, and markers of inflammation among adult Saudis with and without diabetes mellitus type 2," *Advances in Medical Sciences*, vol. 55, no. 2, pp. 179–185, 2010.
- [40] B. M. Y. Cheung, K. L. Ong, A. W. K. Tso et al., "C-reactive protein as a predictor of hypertension in the Hong Kong cardiovascular risk factor prevalence study (CRISPS) cohort," *Journal of Human Hypertension*, vol. 26, no. 2, pp. 108–116, 2011.